[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bone-marrow-transplantation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bone-marrow-transplantation":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,41,68,99,136],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":25,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100145373","biomarkers-in-transplant-recipients-to-improve-outcomes-100145373",false,"NCT01163578","Biomarkers in Transplant Recipients to Improve Outcomes","Study of Biomarkers in Solid Organ and Bone Marrow Transplant Recipients to Better Treat Rejection","Inclusion Criteria:\n\n* Recipients of abdominal, thoracic and bone marrow allografts that are receiving inpatient and outpatient follow-up with routine laboratory tests at the University of Pittsburgh Medical Center.\n* All Ages\n* Subject or parents are able to read and understand the informed consent\n\nExclusion Criteria:\n\n* Subjects and\u002For their parents who are unable to read and understand informed consent.","ALL",{"count":18,"type":19},1200,"ESTIMATED","OBSERVATIONAL","The objective of this study is to evaluate whether certain proteins, expressed in biological tissues can indict a better understanding of the effect of drugs that are used to treat rejection, and of processes leading to rejection and rejection-free outcomes.",[23,24],"Solid Organ Transplantation","Bone Marrow Transplantation",[26,27],"Transplantation","Rejection","RECRUITING","2026-08-05",{"date":31,"type":32},"2026-08-10","ACTUAL",{"date":34,"type":4},"2005-03",{"date":36,"type":19},"2030-03",{"name":38,"class":39},"University of Pittsburgh","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":4},"100646147","model-informed-precision-dosing-on-cyclosporine-therapy-in-hematopoietic-stem-cell-transplant-recipients-100646147","NCT07695571","Model-Informed Precision Dosing on Cyclosporine Therapy in Hematopoietic Stem Cell Transplant Recipients","Hybrid Population Pharmacokinetic,Machine Learning and Deep Learning Modelling to Predict Dosing for the Individualization of Cyclosporine Therapy in Transplant Recipients","Inclusion Criteria:\n\n* • CsA therapy indicated alone or in combination for GVHD prophylaxis.\n\n  * Aged 2-65 years.\n  * Clinically stable after first HSCT.\n\nExclusion Criteria:\n\n* • Inaccurate sampling or dose administration times.\n\n  * Patients with missing key covariates.\n  * Patients lacking sufficient pharmacokinetic or TDM data","2 Years","65 Years",{"count":51,"type":19},300,"The purpose of this study is to develop a new tool that helps doctors choose the right cyclosporine dose for patients undergoing bone marrow transplantation. The tool is designed to predict the best dose using sparse sampling, making it practical for everyday clinical care. It combines information about population pharmacokinetics of cyclosporine with advanced artificial intelligence techniques, including machine learning and deep learning. This tool aims to improve treatment, personalize dosing for each patient, and reduce the risk of graft-versus-host disease.",[24,54],"AML",[56,57],"Clinical Pharmacokinetics","Machine learning","NOT_YET_RECRUITING","2026-07-08",{"date":61,"type":32},"2026-07-10",{"date":63,"type":19},"2026-08-01",{"date":65,"type":19},"2027-06-01",{"name":67,"class":39},"Yasmin medhat munir Mohamed",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":95,"leadSponsor":97,"locationsCount":40},"100636827","phase-2-low-dose-atgptcy-plus-ivarmacitinib-for-agvhd-prevention-in-haplo-pbsct-from-parous-female-donors-100636827","NCT07570745","Low-Dose ATG\u002FPTCy Plus Ivarmacitinib for aGVHD Prevention in Haplo-PBSCT From Parous Female Donors","Low-Dose ATG\u002FPTCy Plus Ivarmacitinib to Prevent Acute Graft-versus-Host Disease Following Haploidentical Peripheral Blood Stem Cell Transplantation From Parous Female Donors: A Prospective, Single-Arm, Multicenter Trial","PARITY","Inclusion Criteria:\n\n1. Age 18-70 years, any gender. Recipients must be diagnosed with hematologic malignancies, such as acute leukemia, myelodysplastic syndrome, or malignant lymphoma, and are planned to undergo haploidentical peripheral blood stem cell transplantation (Haplo-PBSCT).\n2. The donor must be a haploidentical relative within three degrees of kinship and a parous female (having given birth; number of pregnancies not limited), aged 18-55 years, in good health, and cleared by donor screening.\n3. Karnofsky performance status ≥70. The recipient is expected to tolerate transplant-related toxicity. Major organ functions must meet transplantation requirements: cardiac and pulmonary function essentially normal; liver function: ALT\u002FAST \\\u003C2× upper limit of normal, total bilirubin \\\u003C1.5× upper limit of normal; renal function: creatinine clearance \\>50 mL\u002Fmin.\n4. No active infection prior to transplantation (or infection effectively controlled). Chronic infections such as HBV, HCV, or syphilis must be stable under treatment; HBV DNA negative or receiving antiviral therapy is acceptable.\n5. No significant psychiatric disorders; able to understand and voluntarily consent to participate in the study.\n6. The patient has signed the informed consent form and agrees to comply with follow-up and related examinations.\n\nExclusion Criteria:\n\n1. History of prior hematopoietic stem cell transplantation (including autologous or allogeneic transplant).\n2. Presence of donor-specific antibodies (DSA) with a mean fluorescence intensity (MFI) ≥5000.\n3. History of severe hypersensitivity or allergy to JAK inhibitors or the investigational drug.\n4. Prior treatment with JAK1\u002F2 inhibitors.\n5. Uncontrolled comorbidities prior to transplantation, such as uncontrolled hypertension, diabetes complications, or active gastrointestinal ulcer bleeding, which may increase unacceptable risk for trial participation as evaluated by investigators.\n6. Receipt of other investigational drugs within 2 weeks prior to transplantation (excluding standard chemotherapy), or simultaneous participation in other interventional clinical studies, or any other condition deemed by the investigator to make the patient unsuitable for study participation, including poor compliance or inability to complete follow-up (e.g., severe psychiatric disorders preventing cooperation).","18 Years","70 Years",{"count":79,"type":19},82,"INTERVENTIONAL",[82],"PHASE2","Graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT), significantly affecting survival and quality of life. Acute GVHD (aGVHD) typically occurs within 100 days post-transplant, commonly involving skin, gastrointestinal tract, and liver. Chronic GVHD (cGVHD) can appear months to years later.\n\nDespite prophylaxis with calcineurin inhibitors (e.g., cyclosporine or tacrolimus), methotrexate, mycophenolate mofetil, and post-transplant cyclophosphamide (PTCy), patients receiving haploidentical transplantation from parous female donors remain at high risk for moderate-to-severe aGVHD.\n\nJAK1-dependent cytokine signaling (IL-6, IFN-γ) is central to GVHD pathogenesis. Selective JAK1 inhibition may attenuate T cell-mediated inflammation while preserving hematopoiesis. Ivarmacitinib (SHR0302) is a highly selective oral JAK1 inhibitor, showing favorable safety and preliminary efficacy in autoimmune and GVHD settings, making it a candidate for early GVHD prophylaxis.",[85,24],"Graft-Versus-Host Disease(GVHD)",[87,88,89,90],"Graft-versus-host disease","Haploidentical transplantation","Low-dose ATG\u002FPTCy","JAK1 inhibitor (Ivarmacitinib \u002F SHR0302)","2026-05-01",{"date":93,"type":32},"2026-05-06",{"date":91,"type":19},{"date":96,"type":19},"2029-05-01",{"name":98,"class":39},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":40},"100412026","national-longitudinal-cohort-of-hematological-diseases-100412026","NCT04645199","National Longitudinal Cohort of Hematological Diseases","National Longitudinal Cohort of Hematological Diseases (NICHE)","NICHE","Inclusion Criteria:\n\n* Patients who were diagnosed with acute myeloid leukemia, multiple myeloma, hemophilia, aplastic anemia, leukemia, myelodysplastic syndrome, lymphoma, bleeding disorders or received bone marrow transplantation in the investigating hospitals from January 1, 2020.\n\nExclusion Criteria:\n\n* Long-term follow-up information for patients is not available for any reason, such as not being available or having a serious concomitant disease.\n* Alcohol and drug addictions affect their ability to comply with study requirements.\n* According to the investigator, there are conditions that may endanger the patient's safety or affect his\u002Fher compliance.",{"count":108,"type":19},2300,"Background Hematological diseases are disorders of the blood and hematopoietic organs. The current hematological cohorts are mostly based on single-center or multi-center cases, or cohorts with limited sample size in China. There is a lack of comprehensive and large-scale prospective cohort studies in hematology. The purpose of this study is to analyze the incidence and risk factors of major blood diseases, the treatment methods, prognosis and medical expenses of these patients in China.\n\nMethod The study will include patients diagnosed with acute myeloid leukemia, multiple myeloma, hemophilia, aplastic anemia, leukemia, myelodysplastic syndrome, lymphoma, bleeding disorders, autoimmune hemolytic anemia, large granular lymphocyte leukemia, essential thrombocythemia, blood infection or received bone marrow transplantation in the investigating hospitals from January 1, 2020, and collect basic information, diagnostic and treatment information, prognosis information, as well as medical expense information from medical records. In its current form, the NICHE registry incorporates historical data (collected from 2000) and is systematically collecting prospective data in two phases with broadening reach, and prospectively follow-up to collect the prognosis information.",[111,112,113,114,115,116,117,118,119,120,121,24,122,123,124,125,126],"Multiple Myeloma","Acute Myeloid Leukemia","Hemophilia","Hemophilia A","Hemophilia B","Myelodysplastic Syndrome","MDS","Lymphoma","Leukemia","Aplastic Anemia","Bleeding Disorder","Blood Disease Infection","Autoimmune Hemolytic Anemia, AIHA","Essential Thrombocythemia, ET","Large Granular Lymphocyte Leukemia, LGLL","Paroxysmal Nocturnal Hemoglobinuria, PNH","2026-02-09",{"date":129,"type":32},"2026-02-12",{"date":131,"type":32},"2020-12-01",{"date":133,"type":19},"2030-12-01",{"name":135,"class":39},"Institute of Hematology & Blood Diseases Hospital, China",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":144,"targetDuration":146,"studyType":20,"phases":4,"briefSummary":147,"conditions":148,"keywords":156,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":40},"100608743","high-altitude-hematology-observation-stem-cell-transplantation-halo-sct-100608743","NCT07205523","High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)","High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT): A Prospective Real-World Cohort Study in the Qinghai-Tibet Plateau","HALO-SCT","Inclusion Criteria:\n\n1. Patients diagnosed with hematologic diseases who are admitted to the HSCT center of Qinghai University Affiliated Hospital on or after September 1, 2023.\n2. Planned or actual hematopoietic stem cell transplantation (HSCT).\n3. Provision of signed informed consent.\n\nExclusion Criteria:\n\n1. Inability to provide long-term follow-up data due to severe comorbidities or logistical reasons.\n2. Substance abuse compromising adherence.\n3. Any condition judged by investigators to jeopardize safety or compliance.",{"count":145,"type":19},1000,"100 Years","The High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT) study is the first prospective real-world cohort of hematologic diseases and transplantation in the Qinghai-Tibet Plateau. Patients undergoing hematopoietic stem cell transplantation (HSCT) at Qinghai University Affiliated Hospital, together with their donors, are systematically enrolled. The registry collects demographic, diagnostic, treatment, prognosis, and medical expense information, as well as biospecimens for future analyses. Historical data are incorporated, and prospective data collection is ongoing with long-term follow-up planned. The registry is designed as a sustainable research infrastructure to provide comprehensive data on disease incidence, treatment patterns, outcomes, and resource utilization in a high-altitude setting.",[149,150,151,152,113,116,117,118,119,120,153,24,111,154,155],"Hematopoietic Stem Cell Transplantation (HSCT)","Acute Myeloid Leukemia (AML)","Leukemias, Acute Myeloid","Myeloid Leukemias, Acute","Bleeding Disorders","Myeloma, Multiple","Immune Reconstitution",[157],"High-altitude Bone marrow transplantation Allogeneic HSCT Autologous HSCT Immune reconstitution Graft-versus-host disease Relapse Survival Quality of life","2025-09-25",{"date":160,"type":32},"2025-10-03",{"date":162,"type":32},"2023-09-01",{"date":164,"type":19},"2100-12-31",{"name":166,"class":39},"Yigeng Cao,MD,PhD"]